About cell-free
heart valves

Financial Aspects

Does the patient need to pay for the decellularization privately?
The service provided by corlife has been approved for reimbursement by many health insurance companies. If a clinic requests a human decellularized heart valve for implantation, the health insurance covers the costs incurred for the decellularization. In some States, however, the regulations may be different.

Does corlife trade in the heart valves?
No, the tissue is not traded and the commercialization of tissue is a criminal offence. None of the parties involved in the donation or transplantation of the tissue, including the donor, receive financial incentives for tissue donation. Tissue donation is of immense medical and humanitarian value which can and should not be quantified in monetary terms.

How is corlife paid?
Costs are incurred by the respective organizations in the selection of donors, the surgical removal of the tissue, and during implantation. These costs include the necessary examinations, the development of tissue processing procedures and their implementation and in transplantation. The parties involved receive a reasonable fee as compensation for the services provided, as provided by European recommendations and German laws. The set fee for corlife is agreed with the health insurance companies and is the same for all patients. This fee also includes compensation for the financial risks corlife has incurred, e.g. in the development of the human decellularized heart valve.

How is the development of corlife funded?
The development is financed by the company’s founders using own funding and government aid. Public funding plays a considerable role in shouldering the high costs of development and has been pivotal in making the human decellularized heart valve available to patients.
Corlife has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 278453 and from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643597.

EU flag